LUTIKIZUMAB

UNII:	15FAZ725S0
Type:	INGREDIENT SUBSTANCE
Formula:
Preferred Substance Name:	LUTIKIZUMAB
GSRS Full Record:	15FAZ725S0 i

1791411-57-8
A-1234138
ABT-981
Immunoglobulin G1-kappa, anti-[Homo sapiens IL1A (interleukin 1 alpha) and Homo sapiens IL1B (interleukin 1 beta, IL-1B, 1L1F2)], humanized monoclonal antibody, tetravalent bispecific; gamma1 heavy chain (1-577) [humanized VH anti-IL1B (Homo sapiens IGHV3-23*04 (80.60%) -(IGHD)-IGHJ4*01) [8.8.12] (1-119) -6-mer linker (120-125)-Homo sapiens VH anti-IL1A (IGHV3-30*03 (88.80%) -(IGHD)-IGHJ1*01) [8.8.15] (126-247) -Homo sapiens IGHG1*01 (CH1 (248- 345), hinge (346-360), CH2 L1.3>A (364), L1.2>A (365), (361-470), CH3 (471-575), CHS (576-577)) (248-577)], (350-327')-disulfide with kappa light chain (1’-327’) [humanized V-KAPPA anti-IL1B (Homo sapiens IGKV1- 27*01 (82.10%) -IGKJ2*01) [6.3.9] (1'-106') -7-mer linker-Homo sapiens V-KAPPA anti-IL1A (IGKV1-12*01 (92.60%) -IGKJ4*01) [6.3.9] (114'-220')-Homo sapiens IGKC*01, Km3 (221'-327')]; dimer (356-356":359-359")-bisdisulfide
Immunoglobulin, anti-(interleukin 1β/interleukin 1α) (synthetic human A-1234138 heavy chain), disulfide with synthetic human A-1234138 light chain, dimer
LUTIKIZUMAB [USAN]
Lutikizumab [WHO-DD]
lutikizumab [INN]

Note

UNIIs are generated based on scientific identity characteristics using ISO 11238 data elements. UNII availability does not imply any regulatory review or approval. Synonyms and mappings are based on the best public information available at the time of publication. Please report any problems/errors associated with this data to FDA-SRS@fda.hhs.gov.

LUTIKIZUMAB

Synonyms and Mappings

Resources